NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-26 18:39இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Venus Remedies Q2 Standalone PAT Rises 48.3% YoY to ₹28.53 Cr; Revenue Up 13.5%
Venus Remedies reported standalone revenue from operations of ₹218.76 Cr for Q2 FY27 (quarter ended September 30, 2026), up 13.5% YoY compared to ₹192.65 Cr in Q2 FY26. Standalone Net Profit for the quarter reached ₹28.53 Cr, growing 48.3% YoY from ₹19.24 Cr in the prior-year period. Operating performance saw EBITDA expand to ₹46.04 Cr versus ₹31.52 Cr YoY. The auditor highlighted an emphasis of matter regarding ₹28.60 Cr in outstanding share application money pending allotment in German subsidiary Venus Pharma GmbH.
உச்சம் நம்பிக்கை
என்ன மாறியதுVenus Remedies declared financial results for Q2 and H1 ended September 30, 2026, delivering strong double-digit growth in revenues and profits.
ஏன் இது முக்கியம்Demonstrates continued operational momentum in formulations, with standalone quarterly revenue representing ~27% of TTM revenue (₹811 Cr) and reinforcing margin expansion.
Q2 Standalone Revenue: ₹218.76 கோடிQ2 Standalone Net Profit: ₹28.53 கோடிQ2 Standalone Diluted EPS: ₹21.66Q2 வருவாய் vs TTM வருவாய்: ~27.0%Pending Share Application Money (Subsidiary): INR 2,859.72 Lakhs
📅 குறுகிய காலம்Earnings show healthy operational performance with solid YoY profit expansion, likely to be viewed favourably by the market in the near term.
📈 நீண்ட காலம்Sustained execution on IP-led formulations and European restructuring will be key to sustaining ROCE levels and resolving subsidiary financial drag.
⚠ அபாய எச்சரிக்கைகள்
Subsidiary Venus Pharma GmbH facing financial challenges and undergoing restructuring
Auditor emphasis of matter on unallotted share application money of ₹28.60 Cr
👀 கவனிக்க வேண்டியவை
Track the restructuring progress of the European subsidiary Venus Pharma GmbH and subsequent resolution of the ₹28.60 Cr share application money, along with operational margin sustainability in upcoming quarters.
Venus Remedies Secures 5 Marketing Authorisations Across 4 International Markets
Venus Remedies has secured five marketing authorisations across Kazakhstan, Peru, Kuwait, and Argentina. The approved products include critical-care and oncology injectables: Vancomycin and Fluorouracil in Kazakhstan, Fulvestrant in Peru, Methotrexate in Kuwait, and Meropenem in Argentina. These approvals expand the company's existing footprint of over 100 countries across the CIS, Latin America, and Middle East regions. Commercial revenue potential and launch timelines were not disclosed.
உச்சம் நம்பிக்கை
என்ன மாறியதுVenus Remedies received regulatory marketing authorisations for 5 injectable formulations across 4 countries (Kazakhstan, Peru, Kuwait, Argentina).
ஏன் இது முக்கியம்Enables commercial sales of critical care and oncology products in CIS, Latin American, and Middle Eastern markets, supporting international export growth.
Marketing authorisations secured: 5Target countries: 4Existing international footprint: over 100 countriesEstimated financial impact: வெளியிடப்படவில்லை
📅 குறுகிய காலம்Positive sentiment for export capabilities, though commercial revenue impact will take time to materialize.
📈 நீண்ட காலம்Expands geographic diversification and deepens the penetration of Venus's high-margin injectable portfolio across emerging markets.
⚠ அபாய எச்சரிக்கைகள்
Commercial uptake and pricing dynamics in target countries remain undisclosed
Foreign exchange volatility risks on export realizations
👀 கவனிக்க வேண்டியவை
Track the commercial rollout timeline and export revenue contribution from these registrations in upcoming quarterly results.
₹10 Dividend Declared; AGM Set for Aug 20, 2026 with Key Management Appointments
Venus Remedies has scheduled its 37th Annual General Meeting (AGM) for August 20, 2026, to approve a final dividend of ₹10 per share (100% of face value). The record date for dividend eligibility is August 7, 2026. The company is also seeking shareholder approval for the appointment of Mr. Saransh Chaudhary as Executive Director for a five-year term at an annual salary of ₹93 Lacs. This follows a strong financial year where TTM PAT reached ₹103 Cr, a significant increase from ₹45.33 Cr in FY25.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized its dividend payout for FY26 and is restructuring its board with new executive and independent director appointments.
ஏன் இது முக்கியம்The ₹10 dividend reflects the company's improved profitability (TTM PAT up ~127% YoY), while the management appointments ensure leadership continuity for the next five-year cycle.
Dividend per share: ₹10Dividend Yield (approx): 0.6%Proposed ED Salary: ₹93.00 Lacs p.a.ரெக்கார்ட் தேதி: ஆகஸ்ட் 7, 2026TTM PAT: ₹103 கோடி
📅 குறுகிய காலம்The stock may see mild positive interest leading up to the August 7 record date for the ₹10 dividend.
📈 நீண்ட காலம்The company's shift toward IP-led formulations and AMR licensing milestones remains the primary structural driver beyond routine AGM proceedings.
⚠ அபாய எச்சரிக்கைகள்
Management remuneration includes a provision for up to 20% annual increments.
👀 கவனிக்க வேண்டியவை
Investors should note the August 7 record date for dividend eligibility and monitor the AGM for updates on the 'Global Venus Fulfilment Centre' expansion and VRP-034 commercialization progress.
Venus Remedies Q1 FY27 PAT Jumps 118% to ₹25.5 Cr; MOA Revised for Business Alignment
Venus Remedies reported a strong start to FY27 with standalone revenue growing 30.4% YoY to ₹178.80 cr. Net profit surged 118.2% YoY to ₹25.53 cr, with EPS rising to ₹19.40 from ₹8.75 in the year-ago quarter. The board also approved revisions to the Memorandum of Association (MOA) to align with the Companies Act 2013 and accommodate 'proposed business activities'. However, auditors highlighted ₹28.59 cr in pending share allotments for the German subsidiary, which is currently facing financial challenges and undergoing restructuring.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported a significant jump in quarterly profitability and updated its constitutional documents (MOA/AOA) to align with current and future business objectives.
ஏன் இது முக்கியம்The strong earnings growth suggests improved traction in the company's core pharmaceutical formulations. The MOA update provides the legal framework for potential diversification or expansion into new business segments.
📅 குறுகிய காலம்The stock is likely to react positively to the strong earnings beat and significant EPS growth in the immediate term.
📈 நீண்ட காலம்Long-term value depends on the successful commercialization of IP-led research products like VRP-034 and the resolution of financial challenges in the European operations.
⚠ அபாய எச்சரிக்கைகள்
Financial challenges in German subsidiary Venus Pharma GmbH
Pending share allotment of ₹28.59 cr in subsidiary
High dependence on export markets and exchange rate volatility
👀 கவனிக்க வேண்டியவை
Investors should monitor the operational turnaround of the European subsidiaries and the specific 'proposed business activities' hinted at in the MOA revision. The sharp margin expansion in Q1 warrants a check on whether this is sustainable or driven by a one-off product mix.
Venus Remedies Q1 Net Profit Jumps 118% YoY to ₹25.53 Cr; Revenue Up 30%
Venus Remedies reported a strong start to FY27 with standalone revenue growing 30.4% YoY to ₹178.80 Cr. Net profit surged 118.2% YoY to ₹25.53 Cr, driven by significant operational leverage as EBITDA margins expanded from 15.1% to 21.9%. The board also approved updating the Memorandum of Association to include CDMO and CRO activities, signaling a strategic shift. However, auditors highlighted financial challenges at the German subsidiary, where ₹28.60 Cr in share application money remains pending allotment.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company delivered a sharp increase in profitability and margins for Q1 FY27 and formally expanded its business scope to include contract manufacturing and research services.
ஏன் இது முக்கியம்The margin expansion from 15.1% to 21.9% suggests improved pricing power or a better product mix, while the MOA update allows the company to diversify into higher-margin service-based pharmaceutical models.
📅 குறுகிய காலம்The stock is likely to react positively to the substantial YoY growth in both top-line and bottom-line figures.
📈 நீண்ட காலம்The structural shift towards IP-led formulations and CDMO services could re-rate the business if the German subsidiary's financial stress is successfully managed.
⚠ அபாய எச்சரிக்கைகள்
Financial challenges in the German subsidiary (Venus Pharma GmbH)
Pending share allotment of ₹28.60 Cr in subsidiary
Export revenue sensitivity to exchange rate volatility
👀 கவனிக்க வேண்டியவை
Monitor the execution of the European restructuring plan and the timeline for the commencement of new CDMO/CRO service lines as per the revised MOA.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Venus Remedies Secures DSIR Renewal for In-House R&D Unit VMRC
Venus Remedies has successfully renewed its recognition from the Department of Scientific and Industrial Research (DSIR), Government of India, for its R&D wing, Venus Medicine Research Centre (VMRC). This renewal confirms the company's compliance with stringent R&D standards, including qualified staffing and dedicated expenditure accounting. The recognition is pivotal for the development of VRP-034, a novel formulation that already holds a USFDA Qualified Infectious Disease Product (QIDP) designation. Such certifications are essential for pharmaceutical companies to claim tax benefits and access government research grants.
முக்கிய அம்சங்கள்
Renewal of DSIR recognition for the Venus Medicine Research Centre (VMRC) unit.Supports the development of VRP-034, which carries a USFDA QIDP designation.Validates the company's dedicated R&D expenditure and qualified scientific infrastructure.Facilitates ongoing research in antimicrobial resistance and the GASAR surveillance study.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive validation of the company's technical capabilities and R&D infrastructure. Monitor the progress of the VRP-034 pipeline as it represents a significant value driver in the antimicrobial space.
Venus Remedies FY26 Revenue Up 19% to ₹768.7 Cr; Declares ₹10 Dividend
Venus Remedies Limited reported a robust financial performance for the fiscal year ending March 31, 2026, with annual revenue from operations growing 19.3% to ₹768.73 Crores. Profit Before Tax (PBT) saw a significant surge, reaching ₹130.67 Crores compared to ₹69.15 Crores in the previous fiscal year. The company has recommended a final dividend of ₹10 per share (100% of face value), reflecting strong cash flow and profitability. Additionally, the board approved the adoption of a new MOA and AOA to align with the Companies Act 2013.
முக்கிய அம்சங்கள்
Annual revenue from operations increased to ₹768.73 Crores in FY26 from ₹644.47 Crores in FY25.Profit Before Tax (PBT) for the full year nearly doubled to ₹130.67 Crores.Q4 FY26 revenue grew 31.6% YoY to ₹259.01 Crores compared to ₹196.74 Crores in Q4 FY25.Recommended a final dividend of ₹10 per equity share (100% of face value) with a record date of August 7, 2026.Board approved the adoption of new Memorandum and Articles of Association as per Companies Act 2013.
👀 கவனிக்க வேண்டியவை
The significant jump in profitability and the healthy dividend payout indicate strong operational momentum; investors may consider holding the stock to benefit from improved margins and yield.
Venus Remedies FY26 Net Profit Jumps 79% to ₹99.3 Cr; Announces ₹10 Dividend
Venus Remedies reported a stellar performance for FY 2025-26, with annual revenue from operations growing 19.3% to ₹768.73 crore. Net profit for the year surged by 79% to ₹99.30 crore, up from ₹55.50 crore in the previous fiscal, reflecting strong operational leverage. The company has recommended a final dividend of ₹10 per share (100% of face value) and announced the appointment of Mr. Saransh Chaudhary as a Whole Time Director.
முக்கிய அம்சங்கள்
Annual Net Profit surged 79% YoY to ₹99.30 crore in FY26 compared to ₹55.50 crore in FY25.Revenue from operations for the full year grew to ₹768.73 crore from ₹644.47 crore YoY.Q4 FY26 Net Profit stood at ₹43.46 crore, a significant jump from ₹17.72 crore in Q4 FY25.Board recommended a final dividend of ₹10 per equity share with a record date of August 7, 2026.Mr. Saransh Chaudhary appointed as Whole Time Director effective May 26, 2026.
👀 கவனிக்க வேண்டியவை
The significant jump in profitability and healthy dividend payout are strong positive triggers; investors should monitor the sustainability of these margins in upcoming quarters.
Venus Remedies Q4 PAT Jumps 145% YoY to ₹43.46 Cr; Declares ₹10 Dividend
Venus Remedies reported a robust performance for Q4 FY26, with standalone revenue from operations rising 31.6% YoY to ₹259.01 crore. Net profit for the quarter surged to ₹43.46 crore from ₹17.72 crore in the previous year, driven by improved operational efficiencies. For the full fiscal year 2025-26, the company recorded a net profit of ₹99.30 crore, a significant jump from ₹55.50 crore in FY25. The board has also rewarded shareholders with a final dividend of ₹10 per share (100% of face value).
முக்கிய அம்சங்கள்
Standalone Q4 Revenue from operations grew 31.6% YoY to ₹259.01 crore.Net Profit for Q4 FY26 increased by 145% YoY to ₹43.46 crore.Full-year FY26 EBIDTA rose to ₹155.57 crore compared to ₹90.77 crore in FY25.Recommended a final dividend of ₹10 per equity share (100% payout) with a record date of August 7, 2026.Full-year FY26 PAT stood at ₹99.30 crore, representing a 79% growth over the previous fiscal year.
👀 கவனிக்க வேண்டியவை
The strong growth in profitability and the high dividend payout signal robust financial health; investors may consider holding or accumulating on dips. Monitor the upcoming AGM on August 20, 2026, for further management commentary on expansion plans.
Venus Remedies Secures First Global Marketing Approval for Plerixafor in Saudi Arabia
Venus Remedies has received its first-ever global marketing authorization for Plerixafor from the Saudi Food and Drug Authority (SFDA). This specialty oncology injectable is used for stem cell mobilization in patients with multiple myeloma and non-Hodgkin lymphoma. The approval marks a strategic pivot for the company from commodity injectables to high-value specialty therapies in regulated markets. Saudi Arabia represents the largest pharmaceutical market in the GCC, projected to grow to USD 17.1 billion by 2033.
முக்கிய அம்சங்கள்
First global Marketing Authorization for Plerixafor (24mg/1.2ml) secured from Saudi FDATargets the Saudi pharma market, which is projected to reach USD 17.1 billion by 2033 at a 5.0% CAGRAddresses the GCC stem cell therapy market, estimated at USD 1.2 billion in 2024Strategic shift toward higher-value specialty injectables to replace reliance on commodity volumesEnables commercialization through existing international business networks and tertiary oncology centers
👀 கவனிக்க வேண்டியவை
Investors should monitor the revenue contribution from this high-margin specialty segment as it marks a transition in the company's product mix. The successful entry into the regulated Saudi market could serve as a precursor for further international oncology approvals.
Venus Remedies Q3 Standalone Net Profit Jumps 38% YoY to ₹24.92 Crore
Venus Remedies reported a strong standalone performance for the quarter ended December 31, 2025, with net profit rising to ₹24.92 crore from ₹18.02 crore in the previous year. Revenue from operations grew to ₹179.95 crore, supported by improved operational efficiency as EBITDA rose to ₹39.13 crore. However, auditors raised an emphasis of matter regarding the German subsidiary, Venus Pharma GmbH, which has a negative net worth of ₹94.15 lakhs. Management expects a turnaround in the subsidiary's financial position by the end of FY 2025-26 through ongoing restructuring.
முக்கிய அம்சங்கள்
Standalone Net Profit increased by 38.3% YoY to ₹24.92 crore in Q3 FY26.Revenue from operations for the quarter stood at ₹179.95 crore compared to ₹172.20 crore in Q3 FY25.EBITDA for the quarter improved significantly to ₹39.13 crore from ₹24.65 crore in the year-ago period.Auditors flagged a negative net worth of ₹94.15 lakhs at the German subsidiary, Venus Pharma GmbH.Share application money of ₹2,859.72 lakhs remains pending for allotment in the German subsidiary as part of strategic restructuring.
👀 கவனிக்க வேண்டியவை
Investors should view the strong standalone profit growth positively but must monitor the 'Emphasis of Matter' regarding the German subsidiary's going concern status. The stock remains a watch for successful execution of the European operational restructuring by year-end.
Venus Remedies Clarifies Reporting Errors; Q2 Net Profit Rises to ₹20.13 Cr
Venus Remedies has responded to exchange clarifications regarding clerical errors in its Q2 FY26 financial filings, specifically addressing UDIN duplication and document formatting. Despite these administrative issues, the company reported a strong consolidated net profit of ₹20.13 crore for the quarter ended September 2025, up from ₹3.51 crore in the previous year. However, the auditor highlighted that the German subsidiary, Venus Pharma GmbH, has a negative net worth of ₹1.32 crore, creating material uncertainty. Management expects the subsidiary's position to stabilize by the end of FY 2025-26.
முக்கிய அம்சங்கள்
Consolidated Net Profit surged to ₹20.13 crore in Q2 FY26 compared to ₹3.51 crore in Q2 FY25Total Income for the quarter stood at ₹184.48 crore, up from ₹178.03 crore year-on-yearCompany clarified that UDIN duplication in audit reports was a clerical error and re-submitted documentsGerman subsidiary Venus Pharma GmbH reported a negative net worth of ₹1.32 croreBasic EPS for the quarter improved significantly to ₹15.08 from ₹2.63 in the corresponding previous quarter
👀 கவனிக்க வேண்டியவை
Investors should monitor the turnaround progress of the German subsidiary as its negative net worth is a point of concern. The strong quarterly profit growth is positive, and the reporting errors appear to be non-material clerical issues.
Venus Remedies Receives ₹11.78 Crore Incentive Under PLI Scheme
Venus Remedies Limited has been awarded an incentive of ₹11,77,50,000 under the Government of India's Production Linked Incentive (PLI) scheme. This marks the second disbursement for the company, which had previously received ₹10 crore under the same scheme. The total incentive received under this program now stands at approximately ₹21.78 crore. This cash inflow is expected to support the company's operational excellence and innovation in pharmaceutical manufacturing.
முக்கிய அம்சங்கள்
Awarded ₹11,77,50,000 as the second disbursement under the PLI schemePreviously received a sum of ₹10 crore under the same government initiativeTotal incentives received under the PLI scheme now aggregate to ₹21.78 croreThe incentive reinforces the company's commitment to pharmaceutical manufacturing and innovation
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that strengthens the company's cash position and validates its manufacturing capabilities. Monitor the impact on upcoming quarterly margins and any further updates on capacity expansion.
Venus Remedies Secures First Marketing Approval for Ceftazidime + Avibactam in Indonesia
Venus Remedies Limited has received its first marketing authorization in Indonesia for the antibiotic combination Ceftazidime + Avibactam. This product is designed to treat serious infections caused by multi-drug resistant gram-negative pathogens, such as complicated urinary tract infections. Indonesia is a major pharmaceutical market in Southeast Asia, and this approval allows the company to leverage existing distribution partnerships for commercialization. This move strengthens the company's portfolio of high-barrier-to-entry therapies in the strategically important South-East Asian region.
முக்கிய அம்சங்கள்
First marketing authorization for Ceftazidime + Avibactam in the Indonesian marketProduct targets serious multi-drug resistant gram-negative pathogens and urinary tract infectionsIndonesia represents one of the largest pharmaceutical markets in Southeast AsiaCommercialization will be executed through existing distribution partnerships in the region
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive expansion into a high-growth market with specialized therapies. Monitor the impact on international sales and margins in upcoming quarterly reports.
Venus Remedies Receives Final ₹11 Crore Milestone Payment from Cipla for AMR Product
Venus Remedies has successfully received the final milestone payment of ₹11 crore from Cipla Ltd, marking the completion of all commercial milestones under their 2019 licensing agreement. The patented anti-infective product, developed by Venus Medicine Research Centre (VMRC), has treated over one million patients in India to date. This payment serves as a commercial validation of the company's R&D efforts in the Antimicrobial Resistance (AMR) segment. The company is now focusing on its advanced pipeline, including candidates like VRP-034 and MET-X which have received US FDA QIDP designations.
முக்கிய அம்சங்கள்
Received final ₹11 crore milestone payment from Cipla Ltd for a novel AMR-focused anti-infective.Completion of all anticipated commercial milestones agreed upon in the 2019 licensing arrangement for India.The product has delivered therapeutic benefits to over 1 million patients with a favorable safety profile.Reinforces R&D pipeline strength with US FDA QIDP-designated candidates VRP-034 and MET-X.Venus Remedies maintains a commercial presence in over 90 countries with 1,050+ marketing authorizations.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive validation of the company's R&D monetization strategy; focus should now shift to the clinical progress of their US FDA-designated pipeline candidates.
Venus Remedies Limited has successfully concluded all pending Income Tax matters related to previous assessment years following favorable appellate decisions. This resolution has resulted in the complete elimination of a ₹33.44 crore contingent liability, which now stands at nil. Additionally, the company has received refunds for amounts previously deposited under protest, along with applicable interest. This development provides significant financial clarity and strengthens the company's balance sheet by removing potential future tax outflows.
முக்கிய அம்சங்கள்
Complete resolution of all pending Income Tax matters for earlier assessment years.Elimination of ₹33.44 crore in contingent liabilities, reducing the figure to nil.Receipt of tax refunds for amounts previously deposited under protest, including interest.Favorable decisions at the appellate level led to the issuance of final orders by tax authorities.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that improves financial transparency and provides a cash inflow through tax refunds. The removal of a significant contingent liability reduces the risk profile of the company's balance sheet.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
